News
Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
IMV Inc. Announces Changes to Its Board of Directors
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today
Transgene Announces Upcoming Investor Meetings
Regulatory News:
TRANSGENE (Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that Management will participate in
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Evolva publishes agenda for 2023 Annual General Meeting
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Poxel will Report its 2022 Full Year Results on March 23, 2023
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Poxel to Report its 2022 Full Year Results by the End of March 2023
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Transgene: 2022 Full-year Results and Business Update
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial
EQS-News: Abivax adjusts its 2023 Financial Communication Calendar
IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results
IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc